NCT05676333View on ClinicalTrials.gov

Secukinumab in Active Non-segmental Vitiligo

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

December 16, 2017

Study Completion Date

February 22, 2019

Conditions
VitiligoSecukinumab
Interventions
DRUG

Secukinumab

Trial Locations (1)

9000

Department of Dermatology, Ghent University Hospital, Ghent

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital, Ghent

OTHER

NCT05676333 - Secukinumab in Active Non-segmental Vitiligo | Biotech Hunter | Biotech Hunter